Cite
701 Cost-utility analysis of onabotulinumtoxinA versus best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy.
MLA
Freemantle, N., et al. “701 Cost-Utility Analysis of OnabotulinumtoxinA versus Best Supportive Care in the Treatment of Idiopathic Overactive Bladder with Urinary Incontinence among Patients Not Adequately Managed with Anticholinergic Therapy.” European Urology Supplements, vol. 13, no. 1, Apr. 2014, p. e701. EBSCOhost, https://doi.org/10.1016/S1569-9056(14)60691-6.
APA
Freemantle, N., Khalaf, K., Loveman, C., Stanisic, S., Gultyaev, D., Lister, J., Ng-Mak, D., & Drake, M. (2014). 701 Cost-utility analysis of onabotulinumtoxinA versus best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy. European Urology Supplements, 13(1), e701. https://doi.org/10.1016/S1569-9056(14)60691-6
Chicago
Freemantle, N., K. Khalaf, C. Loveman, S. Stanisic, D. Gultyaev, J. Lister, D. Ng-Mak, and M. Drake. 2014. “701 Cost-Utility Analysis of OnabotulinumtoxinA versus Best Supportive Care in the Treatment of Idiopathic Overactive Bladder with Urinary Incontinence among Patients Not Adequately Managed with Anticholinergic Therapy.” European Urology Supplements 13 (1): e701. doi:10.1016/S1569-9056(14)60691-6.